Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Xenon Pharmaceuticals Inc shares valued at $1,004,000 were sold by MORTIMER IAN on Oct 01 ’25. At $40.16 per share, MORTIMER IAN sold 25,000 shares. The insider’s holdings dropped to 31,302 shares worth approximately $1.2 million following the completion of this transaction.
Also, IAN MORTIMER purchased 25,000 shares, netting a total of over 1,004,117 in proceeds.
Before that, SHERRY AULIN had added 2,548 shares to its account. In a trade valued at $94,490, the Former officer bought Xenon Pharmaceuticals Inc shares for $37.08 each.
Analysts at Chardan Capital Markets started covering the stock with ‘”a Buy”‘ outlook in a report released in early May. As of February 11, 2025, Deutsche Bank has initiated its “Buy” rating for XENE.
Analyzing XENE Stock Performance
On last trading session, Xenon Pharmaceuticals Inc [NASDAQ: XENE] plunged -0.93% to $38.3. The stock’s lowest price that day was $37.68, but it reached a high of $39.4058 in the same session. During the last five days, there has been a drop of approximately -10.24%. Over the course of the year, Xenon Pharmaceuticals Inc shares have dropped approximately -8.18%. Shares of the company reached a 52-week high of $44.23 on 10/20/25 and a 52-week low of $26.74 on 04/09/25.
Support And Resistance Levels for Xenon Pharmaceuticals Inc (XENE)
According to the 24-hour chart, there is a support level at 37.52, which, if violated, would cause prices to drop to 36.74. In the upper region, resistance lies at 39.24. The next price resistance is at 40.19. RSI (Relative Strength Index) is 39.24 on the 14-day chart, showing neutral technical sentiment.
Is Xenon Pharmaceuticals Inc subject to short interest?
Stocks of Xenon Pharmaceuticals Inc saw a sharp steep in short interest on 2025-10-15 dropping by -0.89 million shares to 6.15 million. Data from Yahoo Finance shows that the short interest on 2025-09-15 was 7.04 million shares. A decline of -14.51% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.91 of the overall float, the days-to-cover ratio (short ratio) decline to 7.91.
Which companies own the most shares of Xenon Pharmaceuticals Inc (XENE)?
In terms of Xenon Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 55 in the next 12 months, up nearly 42.27% from the previous closing price of $38.66. Analysts anticipate Xenon Pharmaceuticals Inc stock to reach 58 by 2025, with the lowest price target being 44. In spite of this, 10 analysts ranked Xenon Pharmaceuticals Inc stock as Buy at the end of 2025. On October 01, 2024, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $53.
